Radical cell therapy tested for Hard-to-Treat autoimmune conditions
NCT ID NCT07038447
Summary
This early-stage study is testing a new cell therapy called KITE-363 for people with severe autoimmune diseases that haven't improved with standard treatments. The therapy involves modifying a patient's own immune cells to target and reduce harmful B cells that drive diseases like lupus and scleroderma. Researchers will first determine a safe dose and then assess if the treatment can effectively control these difficult conditions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Concord Repatriation General Hospital
Sydney, New South Wales, 2139, Australia
-
Jewish General Hospital
Montreal, H3T1E2, Canada
-
St Vincent's Hospital
Fitzroy, Victoria, 3065, Australia
-
Stanford University
Stanford, California, 94305, United States
-
The Ottawa Hospital, General Campus
Ottawa, K1H 8L6, Canada
Conditions
Explore the condition pages connected to this study.